Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bmj.k3141 | DOI Listing |
Cureus
December 2024
Ophthalmology, University Hospital of Wales, Cardiff, GBR.
Objective This study aims to evaluate the real-world efficacy of ranibizumab biosimilar (Ongavia), compared to aflibercept (Eylea), in the treatment of treatment-naïve neovascular age-related macular degeneration (nAMD) at a busy tertiary eye care centre. Methods A retrospective analysis of medical records from August 2022 to August 2024 was conducted, comparing treatment outcomes in treatment-naive nAMD patients who received either Ongavia or Eylea intravitreal anti-VEGF (vascular endothelial growth factor) injections under a treat-and-extend protocol. Initial and 12-month outcome measures post-treatment initiation were collected, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), prescribed treatment intervals, actual injection frequency, and the average total number of injections per eye over 12 months.
View Article and Find Full Text PDFJ Mark Access Health Policy
December 2024
Department of Economics and Sustainable Development, Harokopio University, 17676 Athens, Greece;
Cureus
November 2024
Health Economics, Semmelweis University, Center for Health Technology Assessment, Budapest, HUN.
Introduction Biologics are substantial in the treatment of different diseases; however, they can burden the healthcare systems due to their high cost. Biosimilars can help healthcare systems keep their financial sustainability and patients access to biological therapies. The research objective is to formulate a framework for integrating biosimilars in the private healthcare sector of the United Arab Emirates (UAE).
View Article and Find Full Text PDFJ Geriatr Oncol
December 2024
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. Electronic address:
Introduction: Opioids and benzodiazepines are commonly prescribed for cancer symptoms. In combination, they can increase the risk of adverse events, particularly for older adults with multimorbidity, who represent most patients with cancer. We aimed to understand cancer care providers' practices for opioid and benzodiazepine coprescribing and mitigating potential harms.
View Article and Find Full Text PDFHealth Serv Res
December 2024
Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Objective: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally.
Study Setting And Design: Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!